TrkB and TrkC agonist antibodies improve function, electrophysiologic and pathologic features in Trembler J mice.
Neurotrophic factors have been considered as potential therapeutics for peripheral neuropathies. Previously, we showed that neurotrophin-3 (NT-3) promotes nerve regeneration in Trembler(J) (Tr(J)) mice and in sural nerves from patients with Charcot-Marie-Tooth 1A (CMT1A). The relatively short plasma half-life of NT-3 and other neurotrophins, however, pose a practical difficulty in their clinical application. Therapeutic agonist antibodies (AAb) targeting the neurotrophic receptors may circumvent this obstacle due to their high specificity and long half-life. Using morphological, electrophysiological studies and functional motor testing, we assessed the efficacy of monoclonal TrkC AAb and TrkB AAb in the Tr(J) mice. Treatments of these AAbs individually or in combination over 20 weeks increased compound muscle action potential (CMAP) amplitude, which correlated with improved grip strength, as compared to the PBS control group. Improvements in CMAP amplitude were most prominent with TrkC AAb treatment. In all treatment groups, distal to the crush site of the sciatic nerves exhibited a significantly greater number of myelinated fibers (MFs) indicating improved regenerative response to injury. In the contralateral intact sciatic nerves, the number of MFs as well as the myelin thickness was also increased significantly by the AAb treatments, suggesting that the hypomyelination/amyelination state of the peripheral nerves in Tr(J) improved. Therapeutic response to AAb combination was often, albeit not always, the most prominent, indicating a non-redundant effect of TrkB and TrkC AAbs. An early functional recovery and the correlative morphological changes of enhanced regeneration were seen with TrkC AAb treatment. These results provide evidence for potential therapeutic use of monoclonal agonist antibodies for neurotrophin receptors in CMT1A and other neuropathies.
Sahenk
Zarife
Z
Research Institute at Nationwide Children's Hospital, The Ohio State University, Columbus, OH 43205, USA. Zarife.Sahenk@NationwideChildrens.org
Galloway
Gloria
G
Edwards
Chris
C
Malik
Vinod
V
Kaspar
Brian K
BK
Eagle
Amy
A
Yetter
Brent
B
Forgie
Alison
A
Tsao
David
D
Lin
John C
JC
D000818:Animals; D000911:Antibodies, Monoclonal / Q000493:pharmacokinetics / Q000494:pharmacology*; D016466:CHO Cells; D002607:Charcot-Marie-Tooth Disease / Q000235:genetics / Q000473:pathology / Q000503:physiopathology; D006224:Cricetinae; D003412:Cricetulus; D004195:Disease Models, Animal; D018737:Hand Strength; D006801:Humans; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D008817:Mice, Mutant Strains; D009048:Motor Skills; D018485:Muscle Fibers, Skeletal / Q000187:drug effects / Q000473:pathology; D020125:Mutation, Missense; D009185:Myelin Proteins / Q000235:genetics; D009186:Myelin Sheath / Q000378:metabolism; D009409:Nerve Crush; D009416:Nerve Regeneration; D009431:Neural Conduction; D051381:Rats; D020813:Receptor, trkB / Q000819:agonists* / Q000276:immunology; D020812:Receptor, trkC / Q000819:agonists* / Q000276:immunology; D012583:Schwann Cells / Q000378:metabolism / Q000473:pathology; D012584:Sciatic Nerve / Q000378:metabolism / Q000473:pathology / Q000503:physiopathology
D000911:Antibodies, Monoclonal; D009185:Myelin Proteins; C489545:Pmp22 protein, mouse; D020813:Receptor, trkB; D020812:Receptor, trkC